

(51) International Patent Classification:
C07K 16/30 (2006.01)(21) International Application Number:
PCT/IB2019/000806(22) International Filing Date:
17 June 2019 (17.06.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
18382431.7 18 June 2018 (18.06.2018) EP
19382131.1 22 February 2019 (22.02.2019) EP(71) Applicants: **MOSAIC BIOMEDICALS SLU** [ES/ES]; Barcelona Science Park, C/baldiri Reixac, 4-8, Torre "i" 7a Planta, 08028 Barcelona (ES). **FUNDACIO PRIVADA INSTITUT D' INVESTIGACIO ONCOLOGIA DE VALL HEBRON** [ES/ES]; Natzaret, 115-117, Edifici Cellex, 08035 Barcelona (ES). **FUNDACIO PRIVADA INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS** [ES/ES]; Passeig Lluís Companys, 23, 08010 Barcelona (ES).(72) Inventors: **SEOANE, Suarez, Joan**; Carrer Natzaret, 115-117, Edifici Cellex, 08035 Barcelona (ES). **ANIDO, Folgueira, Judit**; Carrer Natzaret, 115-117, Edifici Cellex, 08035 Barcelona (ES). **HALLETT, Robin, Matthew**; 101 College Street, Tmdt 11-301, Toronto, ON M5G 1L5 (CA). **BAYLISS, Peter, Edward**; 101 College Street, Tmdt 11-301, Toronto, ON M5G 1L7 (CA). **JEGANATHAN, Ajitha**; 101 College Street, Tmdt 11-301, Toronto, ON M5G 1L7 (CA). **GIBLIN, Patricia, Anne**; 1 Marina Park Drive, Suite 1401, Boston, MA 02210 (US). **HUBER,****Ruano, Isabel**; Carrer Natzaret, 115-117, Edifici Cellex, 08035 Barcelona (ES). **MAGRAM, Jeanne**; 1 Marina Park Drive, Suite 1401, Boston, MA 02210 (US). **PASCUAL, Garcia, Monica**; Carrer Natzaret, 115-117, Edifici Cellex, 08035 Barcelona (ES). **BONFILL, Teixidor, Ester**; Carrer Natzaret, 115-117, Edifici Cellex, 08035 Barcelona (ES). **PLANAS, Rigol, Ester**; Carrer Natzaret, 115-117, Edifici Cellex, 08035 Barcelona (ES).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: METHODS FOR IMPROVING RESPONSE TO ANTI-LIF ANTIBODY TREATMENT IN INDIVIDUALS WITH CANCER




Fig. 20I

(57) Abstract: Described herein are methods of selecting and treating patients likely to respond to treatment with an anti-LIF antibody.

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*